Combined antibiotic therapy spacers either commercial or handmade are superior to monotherapy – a microbiological analysis at the second stage of revision

André Dias Carvalho¹, Ana Ribau¹, Daniel Soares¹,4, Ana Claudia Santos²,4, Miguel Abreu³,4, and Ricardo Sousa¹,4

¹Department of Orthopaedics, Centro Hospitalar Universitário do Porto, Porto, Portugal
²Department of Microbiology, Centro Hospitalar Universitário do Porto, Porto, Portugal
³Department of Infectious Diseases, Centro Hospitalar Universitário do Porto, Porto, Portugal
⁴Porto Bone and Joint Infection Group (GRIP), Centro Hospitalar Universitário do Porto and Grupo TrofaSaúde – Hospitais, Portugal

Correspondence: André Dias Carvalho (diascarvalho.andre@gmail.com)

Received: 7 May 2021 – Revised: 21 July 2021 – Accepted: 22 July 2021 – Published: 10 August 2021

Abstract. Background: Antibiotic-loaded spacers are often used during two-stage exchange for periprosthetic joint infections (PJIs) both for its mechanical properties and as a means of local antibiotic delivery. Purpose: The main goal of this study is to compare the efficacy of different options of antibiotic(s) in spacers concerning the rate of positive cultures at the second stage. Patients and Methods: We retrospectively evaluated two-stage exchange procedures for infected hip or knee arthroplasty performed between 2012 and 2018 in which adequate (at least four deep tissue samples) culture results in both stages were available. The type of spacer and antibiotics used, in addition to several other patient, infection and treatment-related variables, were registered and correlated to microbiological findings in the second stage. Results: Fifty-eight cases were included with a 19.0 % (11/58) overall rate of positive cultures during reimplantation. With a mean follow-up of 46 months, failure rate was significantly higher at 63.6 % (7/11) in cases with positive cultures at reimplantation compared to 4.3 % (2/47) for those with negative cultures during reimplantation (p < 0.001). The need for additional surgeries was also significantly higher (odds ratio (OR) 122.67, confidence interval (CI) 95 % 11.30–1331.32, p < 0.001). Multi-variable analysis revealed antibiotics in the spacers were the main independent prognostic risk factor associated with positive cultures at the second stage with an advantage for combined antibiotics. Monotherapy is associated with failure with an OR of 16.99. Longer time between surgeries did not have statistical significance (p = 0.05), and previous surgical treatment for PJI, presence of difficult-to-treat microorganism(s), duration of systemic antibiotic therapy or even treatment within a dedicated septic team were not shown to be independent risk factors. Among combined antibiotic spacers, there were no significant differences between the rate of positive cultures during the second stage, comparing commercially available vancomycin/gentamicin spacers to hand-mixed vancomycin/meropenem manufactured spacers (8.3 % [2/24] vs. 15.0 % [3/20], p = 0.68). Conclusions: Results show that combined antibiotic therapy spacers are advantageous when compared to gentamicin monotherapy as they produce significantly lower rates of subsequent positive cultures during the second stage. Hand-mixed high-dose vancomycin/meropenem spacers seem to perform just as well as prefabricated commercially available vancomycin/gentamicin options. Level of Evidence: Therapeutic level III.
1 Introduction

Periprosthetic joint infection (PJI) is a feared complication after total joint arthroplasty. It is indisputably a source of significant deleterious impact on a patient’s health status and quality of life. As the requirements for total joint arthroplasty have been increasing and are expected to continue to steadily increase so will the burden of infection (Patel et al., 2015).

PJI treatment options are greatly limited by the presence of bacterial biofilm on the prosthesis’ surface. These are highly structured communities of microbial cells surrounded by an extracellular matrix that protects them against the host’s immune system action and virtually every antibiotic (Tzeng et al., 2015). Once a mature biofilm is established, removing the implant is the only sensible alternative to eradicate the infection. As such, exchange revision surgery is widely considered to be the gold standard treatment for PJI.

Although one-stage exchange is gaining momentum worldwide, it is mostly used in selected cases, and two-stage revision surgery is still the most common alternative (Leite et al., 2016). When a two-stage strategy is preferred, most surgeons agree on the use of antibiotic-loaded cement spacers with two main objectives in mind: local antibiotic delivery and preservation of joint stability and function between stages that offers some comfort to the patient and prevents soft-tissue contractures. Ultimately, they contribute to an easier and faster second-stage reimplantation surgery (Marczak et al., 2016; Nahhas et al., 2020).

Several different spacer options exist. They can be static or mobile and prefabricated or handmade, and a number of different antibiotics can be incorporated. Despite the large amount of research on this topic, several controversies persist, and it is not clear which (if any) is the best choice. The main goal of this paper is to, based on the rate of positive cultures at the second stage, compare the efficacy of single vs. combined antibiotics in eradicating PJI. A secondary goal is to ascertain a possible performance difference between prefabricated and handmade spacers.

2 Material and methods

We retrospectively evaluated all two-stage exchange procedures performed at our university hospital for infected hip or knee arthroplasty between 2012 and 2018. Basic patient demographics and comorbidities were registered, as well as infection-related clinical variables such as type of implant (primary or revision prosthesis), whether there were previous surgeries for infection, and microbiological findings in the first and second stages. Methicillin-resistant Staphylococcus aureus, Gram-negative rods, Enterococcus species and fungi were further classified as difficult-to-treat microorganisms.

Treatment-related information such as duration of first-stage surgery, the type (commercially available or handmade) and antibiotic(s) used in the spacer, time interval between stages, duration of systemic antibiotic therapy and whether the patient was operated on by a dedicated septic team were also thoroughly collected. Cases in which no cultures were obtained during reimplantation and cases without sufficient data on antibiotic(s) used in cement spacers were excluded.

2.1 Definitions

Definitive diagnosis of PJI during the first stage was based on the diagnostic criteria proposed back in 2011 by the Musculoskeletal Infection Society (Parvizi et al., 2011) and further refined in 2013 (Gehrke and Parvizi, 2013). Given the lack of accuracy of aforementioned criteria to identify persistent infection at the second stage (George et al., 2016), a different criterion was adopted. Reimplantation cultures were considered significant when (i) at least one of the virulent microorganisms was isolated (Staphylococcus aureus, Gram-negative rods, Enterococcus species, Streptococcus species or Candida species) or (ii) at least two of the low-virulence microorganisms with the same antibiotic were isolated (coagulase-negative staphylococci, Corynebacterium species, Cutibacterium acnes or other).

Failure after reimplantation was defined as the need for additional surgical intervention and/or the need for suppressive antibiotic therapy due to persistent clinical signs of infection.

2.2 Surgical and microbiology sampling protocol

During the first stage, no perioperative antibiotic prophylaxis is generally used. Institutional guidelines are to start broad-spectrum antibiotics (vancomycin and piperacillin/tazobactam) after deep tissue sampling (favouring the bone-implant interface) and prosthesis removal for sonication. The choice of which specific type of spacer to use was at the surgeon’s personal discretion based on availability and specific considerations in each case.

Systemic antibiotic therapy was prescribed based on antibiotic sensitivity profile of isolated microorganisms. The timing of reimplantation was decided by treating physicians and was mostly based on trending serum inflammatory parameters and clinical impression in each case.

Second-stage surgery is routinely performed under cefazolin prophylaxis, followed by a broad-spectrum antibiotic regimen despite initial microbiology results that are continued until intraoperative culture results. At least four tissue samples (or three tissue samples and sonication of the removed implant and/or spacer) were required to classify them as adequate sampling in either the first or the second stage.

All patients who had positive cultures at reimplantation were subsequently treated with appropriate antibiotics for an additional 12 to 24 weeks.

2.3 Statistical analysis

IBM SPSS Statistics 24 was used for the statistical analysis. The groups were compared using the Student’s t test (quan-
Table 1. Demographic and clinical information of the 58 patients included.

| Demographic and Clinical Information | Value |
|--------------------------------------|-------|
| Age (years)                          | 67.2 (39–85) |
| Female gender (%)                    | 32 (55.2 %) |
| ASA classification ≥ 3               | 29 (50 %) |
| BMI ≥ 30                             | 20 (34.5 %) |
| Diabetes mellitus                    | 26 (44.8 %) |
| Hip : knee ratio                     | 22 : 36 |
| Primary : revision prosthesis        | 41 : 17 |
| Previous surgical treatment for PJI (%) |  |
| - None                               | 30 (51.7 %) |
| - DAIR                               | 22 (37.9 %) |
| - Revision surgery                   | 6 (10.4 %) |
| Difficult-to-treat microorganism(s) (%) | 15 (25.9 %) |
| Duration of first stage (min)²       | 162 (±50) |
| Antibiotics in spacer (%)            |  |
| - Monotherapy                        | 14 (24.1 %) |
| - Combined                           | 44 (75.9 %) |
| Duration of systemic antibiotics (days)³ | 70 (42–171) |
| Time between surgeries (days)¹       | 143 (56–524) |

¹ expressed as mean (range); ² expressed as mean (± standard deviation); ³ expressed as mean (range); ASA – American Society of Anesthesiologists; BMI – body mass index; PJI – periprosthetic joint infection; DAIR – debridement, antibiotics and implant retention.

Table 2. Microorganisms isolated in the first stage of the 58 patients included.

| Microorganism(s) | Overall (n = 67) |
|------------------|------------------|
| Gram positive    | 56 (83.6 %)      |
| *Staphylococcus aureus* (SA) | 18 (26.9 %) |
| MRSA             | 4 (6.0 %)        |
| MSSA             | 14 (20.9 %)      |
| CoN Staphylococci (S) | 25 (37.3 %) |
| MR CoNS          | 7 (10.4 %)       |
| MS CoNS          | 18 (26.9 %)      |
| Other Gram positive | 13 (19.4 %)  |
| *Streptococcus* species | 9 (13.4 %) |
| *Enterococcus* species | 3 (4.5 %)   |
| *Corynebacterium* species | 1 (1.5 %) |
| Gram negative    | 10 (14.9 %)      |
| *Enterobacteriaceae* | 6 (9.0 %)   |
| Escherichia coli | 2 (3.0 %)        |
| *Klebsiella* species | 2 (3.0 %) |
| *Proteus* species | 1 (1.5 %)       |
| *Pantoea* species | 1 (1.5 %)        |
| *Pseudomonas* species | 4 (5.9 %) |
| Fungi            | 1 (1.5 %)        |
| *Candida albicans* | 1 (1.5 %)    |
| Polymicrobial*   | 12 (18.7 %)      |

MR – methicillin-resistant; MS – methicillin-sensitive; CoN – coagulase negative; * refers to number of polymicrobial PJI cases; specific microorganisms involved are reflected under their respective categories.

Results

Medical charts of 81 two-stage exchange total hip arthroplasty (THA) or total knee arthroplasty (TKA) cases were reviewed. Thirteen cases were excluded because of inadequate cultures obtained during second-stage surgery, and 10 cases were excluded due to a lack of reliable information on the antibiotic(s) used in the cement spacer. Demographic and clinical information of the 58 patients ultimately included in the final analysis are shown in Table 1.

The majority of cases had undergone previous surgical treatment for PJI, mostly failed previous debridement and implant retention but also failed previous two-stage exchange.

Concerning type of spacer, prefabricated commercially available gentamicin-loaded spacers were applied in 14 cases (24.1 %), and gentamicin- and vancomycin-loaded spacers were used in 24 cases (41.4 %). Hand-mixed high-dose vancomycin (3 g) plus meropenem (2 g) per 40 g of low-dose gentamicin (0.5 g) polymethyl methacrylate (PMMA) manufactured spacers were used in 20 cases (34.5 %). Dual antibiotic therapy spacers were less often used in THA than TKA (54.5 % [12/22] vs. 88.9 % [32/36], p < 0.001). At the beginning of the study (2012), at our institution, we used a specific commercial hip spacer with very good mechanical characteristics but with only one antibiotic (gentamicin).

Microbiological findings in the first stage are summarized in Table 2. PJI cases during the first stage categorized as difficult-to-treat microorganism included three cases of methicillin-resistant *Staphylococcus aureus*, two including *Enterococcus* species, six cases involving Gram-negative rods, one fungi case and three polymicrobial infections including any of the previous bacteria.

There was significant growth in cultures taken during the second stage in 11 (19.0 %) cases. Failure rate after reimplantation was 15.5 % (9/58) with a mean follow-up of 46 months (interquartile range 24–48 months) after the second stage. It was significantly higher in those patients who had positive cultures during the second stage (63.6 % [7/11]) compared to those with negative cultures (4.3 % [2/47]). Despite the fact that all positive cases were subsequently treated with systemic antibiotics for a period of 12 to 24 weeks (OR 2.5, CI 95 % 1.26–3.80, p < 0.001). The likelihood of ad-
Table 3. Analysis of risk factors for positive cultures in the second stage in all patients.

| Positive cultures | Negative cultures | Univariate analysis | Multivariable analysis |
|-------------------|-------------------|---------------------|------------------------|
| (n = 11)          | (n = 47)          | P value | Odds ratio | 95 % CI | P value | Odds ratio | 95 % CI |
| Age (years)¹      | 66.5 (52–79)      | 67.3 (39–85)       | 0.78 | – | – | – | – |
| Female gender (%) | 8 (72.7 %)        | 24 (51.1 %)        | 0.31 | – | – | – | – |
| ASA classification ≥ 3 (%) | 7 (63.3 %) | 22 (46.8 %) | 0.72 | – | – | – | – |
| BMI ≥ 30 (%)      | 3 (27.2 %)        | 17 (36.2)          | 0.73 | – | – | – | – |
| Diabetes mellitus | 3 (27.2 %)        | 23 (48.9)          | 0.31 | – | – | – | – |
| Revision prosthesis (%) | 4 (36.4 %) | 13 (27.7 %) | 0.71 | – | – | – | – |
| Hip location (%)  | 7 (63.6 %)        | 15 (31.9 %)        | 0.05 | 3.73 | (0.95–14.74) | 0.42 | 4.37 | (0.12–153.39) |
| Previous surgical treatment for PJI (%) | | | | | | | |
| – Yes             | 8 (72.7 %)        | 20 (42.6 %)        | 0.07 | 3.60 | (0.85–15.31) | 0.17 | 47.15 | (2.24–993.76) |
| – No              | 3 (27.3 %)        | 27 (57.4 %)        | – | – | – | – | – |
| Difficult-to-treat microorganism(s) (%) | 5 (45.5 %) | 10 (23.4 %) | 0.13 | 3.08 | (0.79–12.22) | 0.14 | 0.20 | (0.02–1.74) |
| Duration of first stage > 75th percentile (%) | 1 (9.1 %) | 13 (27.7 %) | 0.27 | – | – | – | – |
| Antibiotics in spacer (%) | | | | | | | |
| – Monotherapy     | 6 (54.5 %)        | 8 (17.0 %)         | 0.02 | 0.20 | (0.05–0.79) | 0.03 | 16.99 | (1.87–901.83) |
| – Combined        | 5 (45.5 %)        | 39 (83.0 %)        | – | – | – | – | – |
| Dedicated septic team (%) | 3 (27.3 %) | 28 (59.6 %) | 0.05 | 3.93 | (0.92–16.74) | 0.43 | – | – |
| Duration of systemic antibiotics (days)² | 93 (±51) | 64 (±28) | 0.09 | – | – | 0.26 | – | – |
| Time between surgeries (days)² | 220 (±121) | 125 (±79) | 0.03 | – | – | 0.05 | – | – |

¹ expressed as mean (range); ² expressed as mean (± standard deviation); ASA – American Society of Anesthesiologists; BMI – body mass index; PJI – periprosthetic joint infection.

ditional surgeries was significantly higher (OR 122.67, CI 95 % 11.30–1331.32, p < 0.001) in this subgroup of patients. Variables possibly associated with positive cultures during the second stage in the univariate analysis were hip location, antibiotic monotherapy in spacer, treatment performed by a non-dedicated septic team and longer time between first and second stage (Table 3).

Multivariable analysis, performed including variables with p ≤ 0.2, substantiates gentamicin monotherapy in spacer, treatment performed by a non-dedicated septic team and longer time between first and second stage (Table 3). Among patients receiving combined antibiotic therapy spacers, no other registered variable appeared as a significant risk factor (Table 4).

Further analysis exploring combined antibiotic therapy spacers found no statistically significant difference between the gentamicin- and vancomycin-loaded prefabricated commercially available spacers and the high-dose vancomycin...
and meropenem hand-mixed manufactured spacers (8.3 % [2/24] vs. 15.0 % [3/20], \( p = 0.68 \)). Despite the rate of positive cultures during the second stage, we compared the complication rate between commercial spacers and hand-mixed manufactured spacers. The overall rate of complications was 8.6 % (5/58) (3 dislocations of hip spacers and 2 fractures) and there is no difference between the two types of spacers.

When focusing on the influence of the type of microorganisms, we found no significant difference of the presence of classically considered difficult-to-treat bacteria. We found that 81.8 % (9/11) of microorganisms isolated during second-stage cultures were some kind of persistent microorganism already present in the first stage (Table 5). As mentioned above, systemic antibiotic therapy after first stage was prescribed based on antibiotic sensitivity profile of isolated microorganism, and was never less than 6 weeks. Timing of reimplantation was decided by treating physician(s) and was mostly based on trending serum inflammatory parameters and clinical impression in each case.

When the microorganisms isolated in the first stage are resistant to antibiotics in the spacer, the risk of positive cultures on reimplantation is significantly higher despite appropriate systemic antibiotic therapy between stages (OR 18.75, 95 % CI 2.954–118.99, \( p = 0.002 \)). More detailed information on the 11 cases with positive cultures during the second stage can be found on Table 4. Naturally, finding persistent resistant microorganisms is more frequent when using monotherapy spacers (four out of six) than in dual antibiotic spacers (one out of five).

## Discussion

Periprosthetic joint infection (PJI) treatment is complex and laborious. Although several controversies still exist, there is a consensus that chronic infections, with established and mature biofilm, require complete exchange of the implant. Currently, the most popular strategy is still to perform one initial surgery to accomplish exhaustive surgical debridement and complete implant removal followed by a second surgery in a few weeks to reimplant a new prosthesis after the infection is deemed to be cured, i.e. a two-stage exchange. When this two-stage strategy is preferred, the goal of the interim period between surgeries is to eradicate infection while optimizing local conditions for a successful revision surgery.

A major potential advantage of the use of spacers is the possibility of local antibiotic therapy. The local antibiotic delivery theoretical advantage is that it can result in very high drugs concentration at the site of infection with low

---

**Table 4.** Analysis of risk factors for positive cultures in the second-stage surgery among patients with combined antibiotics in spacer.

| Risk Factor                          | Overall (\( n = 44 \)) | Positive cultures (\( n = 5 \)) | Negative cultures (\( n = 39 \)) | \( P \) value |
|--------------------------------------|-------------------------|---------------------------------|----------------------------------|--------------|
| Age (years)\(^1\)                    | 67.2 (39–85)            | 68.8 (61–75)                    | 68.7 (39–85)                     | 1.00         |
| Female gender (%)                    | 26 (59.1 %)             | 5 (100 %)                       | 21 (53.8 %)                      | 0.06         |
| ASA classification \( \geq 3 \) (%)  | 22 (50 %)               | 3 (60.0 %)                      | 19 (48.7 %)                      | 1.00         |
| BMI > 30 (%)                         | 18 (40.1 %)             | 2 (40.0 %)                      | 16 (41.0 %)                      | 1.00         |
| Diabetes mellitus                    | 21 (47.7 %)             | 2 (40.0 %)                      | 19 (48.7 %)                      | 0.35         |
| Revision prosthesis (%)              | 12 (27.3 %)             | 2 (40.0 %)                      | 10 (25.6 %)                      | 1.00         |
| Hip location (%)                     | 12 (27.3 %)             | 3 (60.0 %)                      | 9 (23.1 %)                       | 0.12         |
| Previous surgical treatment for PJI (%) |                      |                                 |                                  |              |
| – Yes                                | 20 (45.5 %)             | 4 (80.0 %)                      | 16 (41.0 %)                      | 0.65         |
| – No                                 | 24 (54.5 %)             | 1 (20.0 %)                      | 23 (59.0 %)                      |              |
| Difficult-to-treat microorganism(s) (%) | 12 (27.3 %)             | 2 (40.0 %)                      | 10 (25.6 %)                      | 0.59         |
| Duration of first stage > 75th percentile (%) | 11 (25 %)             | 2 (40.0 %)                      | 9 (23.1 %)                       | 1.00         |
| Dedicated septic team (%)            | 30 (68.1 %)             | 3 (60.0 %)                      | 27 (69.2 %)                      | 0.64         |
| Duration of systemic antibiotics (days)\(^2\) | 60 (42–171)             | 59 (± 26)                       | 68 (± 47)                        | 1.00         |
| Time between surgeries (days)\(^2\)  | 121 (56–392)            | 112 (± 75)                      | 192 (± 90)                       | 0.35         |

\(^1\)Expressed as mean (range); \(^2\) expressed as mean (± standard deviation); ASA – American Society of Anesthesiologists; BMI – body mass index; PJI – periprosthetic joint infection.
Table 5. Microbiological findings at the first stage and type of spacer used in those cases with positive culture cases at the second stage.

| Antibiotic(s) in spacer | Microorganism(s) at first stage | Sensitivity* to antibiotics in spacer | Microorganism(s) at second stage | Sensitivity* to antibiotics in spacer | Microorganism at first vs. second stage |
|-------------------------|---------------------------------|--------------------------------------|----------------------------------|--------------------------------------|----------------------------------------|
| 1 Gentamicin            | Staphylococcus aureus Streptococcus gordonii | Sensible                             | Staphylococcus aureus            | Sensible                             | Likely persistent                      |
| 2 Gentamicin            | Pseudomonas aeruginosa Staphylococcus aureus | Resistant                            | Staphylococcus aureus            | Resistant                             | Likely persistent                      |
| 3 Gentamicin            | Staphylococcus aureus            | Resistant                            | Staphylococcus aureus            | Resistant                             | Likely persistent                      |
| 4 Gentamicin + vancomycin | Staphylococcus lugdunensis      | Sensible                            | Enterococcus faecalis            | Resistant                             | Different                              |
| 5 Gentamicin + vancomycin | Streptococcus sanguinis Staphylococcus aureus | Sensible                            | Staphylococcus aureus            | Sensible                             | Likely persistent                      |
| 6 Vancomycin + carabapen (+ gentamicin) | Staphylococcus aureus | Sensible                            | Staphylococcus epidermidis Staphylococcus capitis | Sensible                            | Different                              |
| 7 Gentamicin            | Staphylococcus aureus            | Sensible                            | Staphylococcus aureus            | Sensible                             | Likely persistent                      |
| 8 Gentamicin + vancomycin | Staphylococcus epidermidis Corynebacterium striatum Candida albicans | Resistant                            | Candida albicans                  | Resistant                             | Likely persistent                      |
| 9 Gentamicin            | Staphylococcus epidermidis Staphylococcus haemolyticus Corynebacterium striatum | Resistant                            | Corynebacterium striatum          | Resistant                             | Likely persistent                      |
| 10 Gentamicin           | Klebsiella pneumoniae Staphylococcus epidermidis | Resistant                            | Klebsiella pneumoniae             | Resistant                             | Likely persistent                      |
| 11 Vancomycin + carabapen (+ gentamicin) | Staphylococcus caprae | Sensible                            | Staphylococcus caprae Proteus mirabilis | Sensible                            | Likely persistent                      |
seem to be a better alternative in treating periprosthetic joint infections as they result in significantly lower rates of positive cultures taken in the second-stage surgery and lower risk of subsequent failure. Both prefabricated commercially available and surgeon-made antibiotic hand-mixed spacers seem to be valid options as there was no significant performance difference between them.

Data availability. In this paper, we worked with the data that is published (in tables); we did not use any other data to make the statistical analysis or get the results. The data used to support the findings of this study are included in the article.

Author contributions. ADC developed the study design, performed the retrospective analysis, and wrote the manuscript. AR provided the statistical analysis and manuscript editing. DS provided conceptualization and project oversight. ACS helped with manuscript writing and editing. MA helped to formulate the hypothesis and study design. RS helped with methodology, conceptualization, resources, manuscript editing, and project supervision.

Competing interests. The contact author has declared that neither they nor their co-authors have any competing interests.

Disclaimer. Publisher’s note: Copernicus Publications remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Review statement. This paper was edited by Parham Sendi and reviewed by two anonymous referees.

References

Akgun, D., Müller, M., Perka, C., and Winkler, T.: A positive bacterial culture during re-implantation is associated with a poor outcome in two-stage exchange arthroplasty for deep infection, Bone Joint J., 99, 1490–1495, https://doi.org/10.1302/0301-620X.99B11.BJJ-2017-0243-R1, 2017.

Cui, Q., Mihalko, W., Shields, J. S., Ries, M., and Saleh, K. J.: Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty, J. Bone Joint Surg. Am., 89, 871–882, 2007.

Gehrke, T. and Parvizi, J.: Proceedings of the International Consensus Meeting on Periprosthetic Joint Infection, available at: https://www.efort.org/wp-content/uploads/2013/10/Philadelphia_Consensus.pdf (last access: 1 March 2021), 2013.

George, J., Kwiecien, G., Klika, A. K., Ramanathan, D., Bauer, T. W., Barsoum, W. K., and Higuera, C. A.: Are Frozen Sections and MSIS Criteria Reliable at the Time of Reimplantation of Two-stage Revision Arthroplasty?, Clin. Orthop. Relat. Res., 474, 1619–1626, 2016.

Goltzer, O., McLaren, A., Overstreet, D., Galli, C., and McMenemy, R.: Antimicrobial Release From Prefabricated Spacers Is Vari-
able and the Dose Is Low, Clin. Orthop. Relat. Res., 473, 2253–2261, 2015.

Holleyman, R. J., Deehan, D. J., Charlett, A., Gould, K., and Baker, P. N.: Does pre-operative sampling predict intra-operative cultures and antibiotic sensitivities in knee replacements revised for infection?: a study using the NJR dataset, Knee Surg. Sports Traumatol. Arthrosc., 24, 3056–3063, 2016.

Leite, P., Figueiredo, S., and Sousa, R.: Prosthetic Joint Infection: Report on the One versus Two-stage Exchange EBJIS Survey, J. Bone Joint Infect., 1, 1–6, 2016.

Lourtet-Hascoet, J., Felice, M. P., Bicart-See, A., Bouige, A., Giordano, G., and Bonnet, E.: Species and antimicrobial susceptibility testing of coagulase-negative staphylococci in periprosthetic joint infections, Epidemiol. Infect., 146, 1771–1776, https://doi.org/10.1017/S0950268818001437, 2018.

Marczak, D., Synder, M., Sibinski, M., Wasko, M., Polguj, M., and Kowalczewske, J.: Comparison of patients treated with or without a spacer in two stage revision hip arthroplasty for periprosthetic joint infection, J. Infection, 73, 520–522, https://doi.org/10.1016/j.jinf.2016.09.006, 2016.

Matter-Parrat, V., Ronde-Oustau, C., Boeri, C., Gaudias, J., and Jenny, J. Y.: Agreement between pre-operative and intra-operative bacteriological samples in 85 chronic periprosthetic infections, Orthop. Traumatol.-Sur., 103, 301–305, https://doi.org/10.1016/j.otsr.2016.11.022, 2017.

Nahas, C. R., Chalmers, P. N., Parvizi, J., Sporer, S. M., Berend, K. R., Moric, M., Chen, A. F., Austin, M. S., Deirmengian, G. K., Morris, M. J., and Della Valle, C. J.: A Randomized Trial of Static and Articulating Spacers for the Treatment of Infection Following Total Knee Arthroplasty, J. Bone Joint Surg., 102, 778–787, https://doi.org/10.2106/JBJS.19.00915, 2020.

Nelson, C. L., Jones, R. B., Wingert, N. C., Foltzer, M., and Bowen, T. R.: Sonication of antibiotic spacers predicts failure during two-stage revision for prosthetic knee and hip infections, Clin. Orthop. Relat. Res., 472, 2208–2214, 2014.

Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Stockelberg, J. M., Rao, N., Hanssen, A., and Wilson, W. R.: Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America, Clin. Infect. Dis., 56, e1–e25, 2013.

Parvizi, J., Zmistowski, B., Berbari, E. F., Bauer, T. W., Springer, B. D., Della Valle, C. J., Garvin, K. L., Mont, M. A., Wongworawat, M. D., and Zalavras, C. G.: New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society, Clin. Orthop. Relat. Res., 469, 2992–2994, 2011.

Patel, A., Pavlou, G., Mujica-Mota, R. E., and Toms, A. D.: The epidemiology of revision total knee and hip arthroplasty in England and Wales: a comparative analysis with projections for the United States. A study using the National Joint Registry dataset, Bone Joint j., 97, 1076–1081, https://doi.org/10.1302/0301-620X.97B8.35170, 2015.

Soares, D., Leite, P., Barreira, P., Aido, R., and Sousa, R.: Antibiotic-loaded bone cement in total joint arthroplasty, Acta Orthop. Belg., 81, 184–190, 2015.

Sorli, L., Puig, L., Torres-Claramunt, R., Gonzalez, A., Alier, A., Knobel, H., Salvado, M., and Horcajada, J. P.: The relationship between microbiology results in the second of a two-stage exchange procedure using cement spacers and the outcome after revision total joint replacement for infection: the use of sonication to aid bacteriological analysis, J. Bone Joint Surg. Br., 94, 249–253, 2012.

Sousa, R., Pereira, A., Massada, M., Vieira da Silva, M., Lemos, R., and Costa e Castro, J.: Empirical antibiotic therapy in prosthetic joint infections, Acta Orthop. Belg., 76, 254–259, 2010.

Tzeng, A., Tzeng, T. H., Vasdev, S., Korth, K., Healey, T., Parvizi, J., and Saleh, K. J.: Treating periprosthetic joint infections as biofilms: key diagnosis and management strategies, Diagn. Microbiol. Infect. Dis., 81, 192–200, https://doi.org/10.1016/j.diagmicrobio.2014.08.018, 2015.

Wouthuyzen-Bakker, M., Kheir, M. M., Moya, I., Rondon, A. J., Kheir, M., Lozano, L., Parvizi, J., and Soriano, A.: Failure After 2-Stage Exchange Arthroplasty for Treatment of Periprosthetic Joint Infection: The Role of Antibiotics in the Cement Spacers, Clin. Infect. Dis., 68, 2087–2093, 2019.